8-K/A: Cosmos Health Faces Nasdaq Delisting Threat Amid Accounting and Filing Issues

Cosmos Health Inc. is facing potential delisting from Nasdaq due to the late filing of its annual and quarterly reports, alongside the dismissal of its previous auditor and disagreements over accounting practices.

Summary

• Cosmos Health Inc. has filed an amendment to its previous 8-K report to further detail the change in its independent auditor and to report a notice of non-compliance from Nasdaq.
• The company dismissed KPMG as its auditor on April 26, 2024, due to their inability to complete the 2023 audit on time.
• KPMG stated there were disagreements on accounting principles and identified a potential illegal act related to a third-party consignment vendor, which Cosmos Health disputes.
• RBSM LLP was appointed as the new auditor on April 29, 2024, and formally accepted the engagement on May 21, 2024.
• On May 21, 2024, Cosmos Health received a notice from Nasdaq stating they are not in compliance with listing rules due to the late filing of the 10-K for 2023 and the 10-Q for Q1 2024.
• The company has until June 17, 2024, to submit a plan to regain compliance, with a potential extension until October 14, 2024, if the plan is accepted by Nasdaq.

Sentiment

Score: 2

Explanation: The document indicates significant issues with the company's financial reporting and compliance, including auditor dismissal, disagreements, and a delisting notice, which are all negative indicators for investors.

Positives

• RBSM LLP has been appointed as the new independent auditor and has accepted the engagement.
• The company is working to complete and file the required reports to regain compliance with Nasdaq listing rules.
• An independent inventory count was conducted on April 30, 2024, which substantiated the transaction in question.

Negatives

• KPMG was dismissed as the independent auditor due to their inability to complete the 2023 audit on time.
• There were disagreements between Cosmos Health and KPMG regarding accounting principles and a potential illegal act.
• Cosmos Health received a delisting notice from Nasdaq due to the late filing of its 2023 annual report and Q1 2024 quarterly report.
• The company is facing a tight deadline of June 17, 2024, to submit a plan to regain compliance with Nasdaq listing rules.

Risks

• The company faces the risk of being delisted from Nasdaq if it fails to submit an acceptable plan to regain compliance by June 17, 2024.
• The disagreements with the previous auditor, KPMG, could raise concerns about the company's accounting practices.
• The delay in filing financial reports could negatively impact investor confidence and the company's stock price.
• There is a risk that the company may not be able to complete the required filings by the extended deadline of October 14, 2024.

Future Outlook

The company is focused on submitting a plan to Nasdaq to regain compliance and completing the required financial reports. The company is working diligently to complete and file the Annual Report and the Quarterly Report in order to regain compliance with the Nasdaq Listing Rules.

Management Comments

• Greg Siokas, Chief Executive Officer of Cosmos Health, stated: 'We will submit a definitive plan to Nasdaq on a timely basis and proceed to regain compliance.'

Industry Context

The healthcare industry is heavily regulated, and timely financial reporting is critical for maintaining investor confidence and regulatory compliance. The issues faced by Cosmos Health highlight the importance of robust internal controls and effective communication with auditors.

Comparison to Industry Standards

• The dismissal of an auditor and subsequent disagreements are not typical for publicly listed companies, especially those on major exchanges like Nasdaq.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) have faced accounting issues in the past, but these were typically related to revenue recognition or inventory valuation, not a complete breakdown in the audit process.
• The delay in filing financial reports is a serious issue, as companies like Valeant (now Bausch Health) have experienced significant stock price declines and regulatory scrutiny due to similar delays.
• The standard practice is for companies to have a smooth transition between auditors, and the level of disagreement between Cosmos Health and KPMG is unusual and concerning.

Stakeholder Impact

• Shareholders are negatively impacted by the potential delisting and the uncertainty surrounding the company's financial reporting.
• Employees may be concerned about the company's future and job security.
• Customers and suppliers may have concerns about the company's stability and ability to continue operations.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• The company needs to submit a plan to Nasdaq by June 17, 2024, to regain compliance.
• The company must complete and file its 2023 annual report and Q1 2024 quarterly report.
• The company needs to work with its new auditor, RBSM LLP, to complete the audit of the 2023 financial statements.

Key Dates

Keywords

Nasdaq, delisting, auditor, KPMG, RBSM, financial reporting, accounting, compliance, Form 10-K, Form 10-Q